Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.
Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL; CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. Baxter JD, et al. Among authors: mayers dl. AIDS. 2002 May 24;16(8):1131-8. doi: 10.1097/00002030-200205240-00006. AIDS. 2002. PMID: 12004271 Clinical Trial.
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD; 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. Lawrence J, et al. Among authors: mayers dl. N Engl J Med. 2003 Aug 28;349(9):837-46. doi: 10.1056/NEJMoa035103. N Engl J Med. 2003. PMID: 12944569 Free article. Clinical Trial.
Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.
Lawrence J, Hullsiek KH, Thackeray LM, Abrams DI, Crane LR, Mayers DL, Jones MC, Saldanha JM, Schmetter BS, Baxter JD. Lawrence J, et al. Among authors: mayers dl. J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):169-78. doi: 10.1097/01.qai.0000242450.74779.ee. J Acquir Immune Defic Syndr. 2006. PMID: 16951642 Clinical Trial.
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H; RESIST investigator group. Hicks CB, et al. Lancet. 2006 Aug 5;368(9534):466-75. doi: 10.1016/S0140-6736(06)69154-X. Lancet. 2006. PMID: 16890833
HIV-1 drug resistance in variants from the female genital tract and plasma.
Kemal KS, Burger H, Mayers D, Anastos K, Foley B, Kitchen C, Huggins P, Schroeder T, Picchio G, Back S, Gao W, Meyer WA 3rd, Weiser B. Kemal KS, et al. J Infect Dis. 2007 Feb 15;195(4):535-45. doi: 10.1086/510855. Epub 2007 Jan 8. J Infect Dis. 2007. PMID: 17230413
91 results